FN2 Earnings Intelligence
Elanco Animal Health Incorporated financials
Elanco Animal Health Incorporated (ELAN) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $638 | $345 | $352 | $468 | $545 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $4,765 | $4,411 | $4,417 | $4,439 | $4,715 |
| % Growth | 45.6% | -7.4% | 0.1% | 0.5% | 6.2% |
| Gross Profit | $2,631 | $2,498 | $2,486 | $2,436 | $2,593 |
| % Margin | 55.2% | 56.6% | 56.3% | 54.9% | 55.0% |
| EBITDA | - | - | - | - | - |
| % Margin | - | - | - | - | - |
| Net Income | -$472 | -$78 | -$1,231 | $338 | -$232 |
| % Margin | -9.9% | -1.8% | -27.9% | 7.6% | -4.9% |
| Diluted EPS | -$0.97 | -$0.16 | -$2.50 | $0.68 | -$0.47 |
| % Growth | 23.6% | 83.5% | -1,462.5% | 127.2% | -169.1% |
| Operating Cash Flow | $483 | $452 | $271 | $541 | $560 |
| CapEx | $126 | $137 | $140 | $147 | $276 |
| Free Cash Flow | $357 | $315 | $131 | $394 | $284 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | $4,765 | $4,411 | $4,417 | $4,439 | $4,715 |
| Gross Profit | $2,631 | $2,498 | $2,486 | $2,436 | $2,593 |
| EBITDA | - | - | - | - | - |
| Net Income | -$472 | -$78 | -$1,231 | $338 | -$232 |
| Diluted EPS | -$0.97 | -$0.16 | -$2.50 | $0.68 | -$0.47 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $638 | $345 | $352 | $468 | $545 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $6,025 | $5,448 | $5,736 | $4,277 | $3,762 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $483 | $452 | $271 | $541 | $560 |
| Capital Expenditure | $126 | $137 | $140 | $147 | $276 |
| Free Cash Flow | $357 | $315 | $131 | $394 | $284 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 45.6% | -7.4% | 0.1% | 0.5% | 6.2% |
| Gross Margin | 55.2% | 56.6% | 56.3% | 54.9% | 55.0% |
| EBITDA Margin | - | - | - | - | - |
| Net Margin | -9.9% | -1.8% | -27.9% | 7.6% | -4.9% |
| FCF Margin | 7.5% | 7.1% | 3.0% | 8.9% | 6.0% |
| Diluted EPS Growth | 23.6% | 83.5% | -1,462.5% | 127.2% | -169.1% |
Get the ELAN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.